Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Optical Coherence Tomography Drug Eluting Stent Investigation (OCTDESI).

Next Previous
Trial Profile

The Optical Coherence Tomography Drug Eluting Stent Investigation (OCTDESI).

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms OCTDESI
  • Sponsors Boston Scientific Corporation

Most Recent Events

  • 19 Apr 2011 Planned end date changed from 1 Mar 2011 to 1 Feb 2011 as reported by ClinicalTrials.gov.
  • 19 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 17 Jun 2009 Actual number of patients (60) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top